Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Diagnosis of 1 of the following: Intermediate- or high-grade non-Hodgkin's lymphoma (NHL), meeting 1 of the following criteria: In first complete remission (CR) AND at high-risk for relapse, as defined by all of the following criteria: High age-adjusted International Prognostic Index category AND meets the following criteria at diagnosis: Stage III or IV disease Lactic dehydrogenase abnormal Eastern Cooperative Oncology Group (ECOG) score 0-2 Mantle cell histology Primary refractory disease Beyond first CR Low-grade NHL Beyond second relapse Hodgkin's lymphoma Primary refractory disease OR beyond first CR Must have an adequate number of stored autologous peripheral blood stem cells (PBSCs) (i.e., 2.0 x 10^6 hematopoietic progenitor cell antigen (CD34)-positive cells/kg) Patients who are not able to mobilize a sufficient number of PBSCs may use bone marrow instead No active CNS disease NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age 0 to 70 Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic Not specified Hepatic Bilirubin < 2 times upper limit of normal (ULN) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times ULN Renal Creatinine ≤ 2.0 mg/dL Creatinine clearance ≥ 50 mL/min Pulmonary No significant pulmonary dysfunction, defined as Diffusing Capacity the Lung for Carbon monoxide (DLCO) < 60% of predicted Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for ≥ 2 months before and during study participation HIV negative No significant active infection that would preclude PBSC transplantation PRIOR CONCURRENT THERAPY: Biologic therapy No prior transplantation No other concurrent blood products during PBSC transplantation Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy More than 60 days since prior local or regional radiotherapy Surgery Not specified Other More than 30 days since prior investigational drugs No concurrent amphotericin